{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:16:02Z","timestamp":1783296962783,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Aijian Endowment Fund","award":["AJ005"],"award-info":[{"award-number":["AJ005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-026-05402-6","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:43:46Z","timestamp":1778553826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardioprotective effects of platycodon grandiflorum granules in HER2-positive early breast cancer patients receiving trastuzumab plus pertuzumab: study protocol for a double blind randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Wei","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuenong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"3","key":"5402_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"5402_CR2","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1200\/JCO.2016.70.5319","volume":"35","author":"WM Hanna","year":"2017","unstructured":"Hanna WM, Slodkowska E, Lu FI, Nafisi H, Nofech-Mozes S. Comparative analysis of human epidermal growth factor receptor 2 testing in breast cancer according to 2007 and 2013 American society of clinical oncology\/college of American pathologists guideline recommendations. J Clin Oncol. 2017;35(26):3039\u201345.","journal-title":"J Clin Oncol"},{"issue":"5","key":"5402_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1634\/theoncologist.2016-0412","volume":"22","author":"F Lynce","year":"2017","unstructured":"Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, et al. SAFE-HEaRt: rationale and design of a pilot study investigating cardiac safety of HER2 targeted therapy in patients with HER2-positive breast cancer and reduced left ventricular function. Oncologist. 2017;22(5):518\u201325.","journal-title":"Oncologist"},{"key":"5402_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","volume":"16","author":"K Miller","year":"2016","unstructured":"Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, et al. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician\u2019s choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer. BMC Cancer. 2016;16:352.","journal-title":"BMC Cancer"},{"issue":"1","key":"5402_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23(1):92.","journal-title":"Mol Cancer"},{"issue":"2","key":"5402_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"issue":"10","key":"5402_CR7","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","volume":"7","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol. 2021;7(10):1544\u20139.","journal-title":"JAMA Oncol"},{"issue":"11","key":"5402_CR8","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V, Bali Singh T. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: a randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer. 2018;65(11):e27308.","journal-title":"Pediatr Blood Cancer"},{"key":"5402_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"DM Gujral","year":"2018","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy\u2009\u00b1\u2009trastuzumab. Breast. 2018;37:64\u201371.","journal-title":"Breast"},{"key":"5402_CR10","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"1","key":"5402_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28(1):1\u2013e3914.","journal-title":"J Am Soc Echocardiogr"},{"key":"5402_CR12","doi-asserted-by":"publisher","first-page":"153473542094501","DOI":"10.1177\/1534735420945017","volume":"19","author":"W Hao","year":"2020","unstructured":"Hao W, Shi Y, Qin Y, Sun C, Chen L, Wu C, et al. Platycodon grandiflorum protects against anthracycline-induced cardiotoxicity in early breast cancer patients. Integr Cancer Ther. 2020;19:1534735420945017.","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"5402_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s13063-017-2140-z","volume":"18","author":"W Hao","year":"2017","unstructured":"Hao W, Liu S, Qin Y, Sun C, Chen L, Wu C et al. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial. Trials. 2017;18(1):386.","journal-title":"Trials"},{"key":"5402_CR14","unstructured":"U.S. Department of health and human services. Common terminology criteria for adverse events (CTCAE). 2010;(v4.03). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"issue":"9","key":"5402_CR15","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.3390\/ijms22094774","volume":"22","author":"A Indini","year":"2021","unstructured":"Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: changing the destiny of HER2 expressing solid tumors. Int J Mol Sci. 2021;22(9):4774.","journal-title":"Int J Mol Sci"},{"key":"5402_CR16","doi-asserted-by":"publisher","first-page":"1288362","DOI":"10.3389\/fphar.2024.1288362","volume":"15","author":"Y Bao","year":"2024","unstructured":"Bao Y, Chen J, Duan L, Wang F, Lai H, Mo Z, et al. Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2024;15:1288362.","journal-title":"Front Pharmacol"},{"issue":"6","key":"5402_CR17","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/1755-5922.12475","volume":"36","author":"M Yuan","year":"2018","unstructured":"Yuan M, Tse G, Zhang Z, Han X, Wu WKK, Li G, et al. The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis. Cardiovasc Ther. 2018;36(6):e12475.","journal-title":"Cardiovasc Ther"},{"key":"5402_CR18","doi-asserted-by":"publisher","first-page":"e2360","DOI":"10.6061\/clinics\/2020\/e2360","volume":"75","author":"CS Esc\u00f3rcio-Dourado","year":"2020","unstructured":"Esc\u00f3rcio-Dourado CS, Alves-Ribeiro FA, Lima-Dourado JC, Dos Santos AR, de Oliveira Pereira R, Tavares CB, et al. Human epidermal growth factor receptor-2 gene polymorphism and breast cancer risk in women from the Northeastern region of Brazil. Clin (Sao Paulo). 2020;75:e2360.","journal-title":"Clin (Sao Paulo)"},{"issue":"9","key":"5402_CR19","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1093\/oncolo\/oyad086","volume":"28","author":"S Zhou","year":"2023","unstructured":"Zhou S, Cirne F, Chow J, Zereshkian A, Bordeleau L, Dhesy-Thind S, Ellis PM, Mukherjee SD, Aghel N, Leong DP. Three-year outcomes following permissive cardiotoxicity in patients on trastuzumab. Oncologist. 2023;28(9):e712\u201322.","journal-title":"Oncologist"},{"key":"5402_CR20","doi-asserted-by":"publisher","first-page":"154422","DOI":"10.1016\/j.phymed.2022.154422","volume":"106","author":"S Zhang","year":"2022","unstructured":"Zhang S, Chai X, Hou G, Zhao F, Meng Q. Platycodon grandiflorum (Jacq.) A. DC.: A review of phytochemistry, pharmacology, toxicology and traditional use. Phytomedicine. 2022;106:154422.","journal-title":"Phytomedicine"},{"issue":"1","key":"5402_CR21","doi-asserted-by":"publisher","first-page":"14048","DOI":"10.1038\/s41598-023-41013-8","volume":"13","author":"L Jiang","year":"2023","unstructured":"Jiang L, Niu H, Chen Y, Li X, Zhao Y, Zhang C, et al. Quality control of Platycodon grandiflorum (Jacq.) A. DC. based on value chains and food chain analysis. Sci Rep. 2023;13(1):14048.","journal-title":"Sci Rep"},{"issue":"36","key":"5402_CR22","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","volume":"27","author":"M Spielmann","year":"2009","unstructured":"Spielmann M, Roch\u00e9 H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary-no de-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129\u201334.","journal-title":"J Clin Oncol"},{"issue":"14","key":"5402_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Breast cancer international research group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"issue":"6","key":"5402_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","volume":"34","author":"PP Advani","year":"2016","unstructured":"Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;34(6):581\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5402_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/jcm11030847","volume":"11","author":"S Suntheralingam","year":"2022","unstructured":"Suntheralingam S, Fan CS, Calvillo-Arg\u00fcelles O, Abdel-Qadir H, Amir E, Thavendiranathan P. Evaluation of risk prediction models to identify cancer therapeutics related cardiac dysfunction in women with HER2\u2009+\u2009breast cancer. J Clin Med. 2022;11(3):847.","journal-title":"J Clin Med"},{"issue":"1","key":"5402_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","volume":"179","author":"E de Azambuja","year":"2020","unstructured":"de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020;179(1):161\u201371.","journal-title":"Breast Cancer Res Treat"},{"key":"5402_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.mri.2022.12.015","volume":"97","author":"J Kar","year":"2023","unstructured":"Kar J, Cohen MV, McQuiston SA, Malozzi CM. Can global longitudinal strain (GLS) with magnetic resonance prognosticate early cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients, a prospective study? Magn Reson Imaging. 2023;97:68\u201381.","journal-title":"Magn Reson Imaging"},{"issue":"5","key":"5402_CR28","first-page":"677","volume":"2","author":"E Liu Jennifer","year":"2020","unstructured":"Liu Jennifer E, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in cardio-oncology. JACC: Cardio Oncol. 2020;2(5):677\u201389.","journal-title":"JACC: Cardio Oncol"},{"key":"5402_CR29","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jclinepi.2005.12.020","volume":"59","author":"JJ Gagnier","year":"2006","unstructured":"Gagnier JJ, Boon H, Rochon P, Group CONSORT, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59:1134\u201349.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-026-05402-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05402-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05402-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:09:11Z","timestamp":1783296551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-026-05402-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5402"],"URL":"https:\/\/doi.org\/10.1186\/s12906-026-05402-6","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol performed following the principles of the Declaration of Helsinki (Version Edinburgh 2000) and registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR2200061011) on June 2021. This study protocol also approved by the Ethical Committee of Long Hua Hospital (2018LCSY205). An informed consent file will be obtained and kept for each study participant. Any modifications to the protocol or informed consent document must be approved by the relevant ethics committee before being implemented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Model informed consent forms are available upon request to the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}